Sarepta Therapeutics
SRPT
485 hedge funds and large institutions have $14B invested in Sarepta Therapeutics in 2024 Q2 according to their latest regulatory filings, with 120 funds opening new positions, 179 increasing their positions, 130 reducing their positions, and 45 closing their positions.
167% more first-time investments, than exits
New positions opened: 120 | Existing positions closed: 45
100% more call options, than puts
Call options by funds: $650M | Put options by funds: $325M
38% more repeat investments, than reductions
Existing positions increased: 179 | Existing positions reduced: 130
30% more capital invested
Capital invested by funds: $10.8B → $14B (+$3.25B)
17% more funds holding
Funds holding: 415 → 485 (+70)
7% more funds holding in top 10
Funds holding in top 10: 15 → 16 (+1)
5.21% more ownership
Funds ownership: 88.71% → 93.92% (+5.2%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$561M |
| 2 |
State Street
Boston,
Massachusetts
|
+$259M |
| 3 |
Morgan Stanley
New York
|
+$223M |
| 4 |
Jane Street
New York
|
+$75.9M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
+$65.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACA
Avoro Capital Advisors
New York
|
-$173M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
-$152M |
| 3 |
Janus Henderson Group
London,
|
-$138M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$96M |
| 5 |
PA
Perceptive Advisors
New York
|
-$68.1M |
SRPT Hedge Fund Activity: Q2 2024 in Review
485 of the 6,935 institutional investors tracked by Wall St. Rank reported a position in Sarepta Therapeutics (SRPT) for Q2 2024, worth a combined $14B — up 30% from $10.8B a quarter earlier.
Buyers outnumbered sellers: 120 funds opened new SRPT positions and 45 closed out — a net gain of 75 holders — while 179 added to existing stakes and 130 trimmed.
The largest buyer was BlackRock, adding an estimated $561M. The largest seller was Avoro Capital Advisors, cutting an estimated $173M.
- 485 institutional investors held Sarepta Therapeutics (SRPT) as of Q2 2024, up from 415 in Q1 2024.
- Funds reported $14B of Sarepta Therapeutics stock for Q2 2024, up 30% quarter-over-quarter.
- 120 funds opened new Sarepta Therapeutics positions in Q2 2024 and 45 closed out, a net change of +75 holders.
- The largest Sarepta Therapeutics buyer in Q2 2024 was BlackRock, an estimated $561M added.
- The largest Sarepta Therapeutics seller in Q2 2024 was Avoro Capital Advisors, an estimated $173M sold.
Based on aggregated 13F filings for Q2 2024.